Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder
NCT07102524
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
2
Enrollment
OTHER
Sponsor class
Conditions
SLC13A5 Citrate Transporter Disorder
Interventions
DRUG:
TSHA-105
Sponsor
TESS Research Foundation